Island Pharmaceuticals (ASX: $ILA) Third Cohort Dosed in ISLA-101 Study

Island Pharmaceuticals Ltd (ASX: $ILA) has successfully dosed all eight subjects in the third cohort of its Single Ascending Dose study with ISLA-101. The dosing followed confirmation by the Safety Review Committee that the second cohort of healthy subjects demonstrated good tolerability to ISLA-101. Pending review of cohort 3 results, the cohort who received the highest safe dose will return to be treated under fed conditions for final dosing. Island remains on track to report trial data in early 2024.

Executive Commentary on ISLA-101 Study Progress

CEO of Island Pharmaceuticals, Dr David Foster said, 'We are very pleased with how this study is progressing and thank all those volunteers participating in it. With the dose now administered to the third cohort, we are moving swiftly toward the completion of dosing for this study. Based on our current progress, we remain on track to read out data in early 2024.'

Summary of Island Pharmaceuticals' ISLA-101 Study

Island Pharmaceuticals Ltd (ASX: $ILA) has successfully dosed the third cohort in its Single Ascending Dose study with ISLA-101, following confirmation of good tolerability in the second cohort. Pending review of cohort 3 results, the highest safe dose cohort will return for final dosing under fed conditions. The company remains on track to report trial data in early 2024. ISLA-101, a repurposed drug candidate for the prevention and treatment of dengue fever and other mosquito-borne diseases, is progressing towards the completion of dosing for the study, paving the way for Island's planned Phase 2a PEACH clinical trial.